HiFiBiO Therapeutics, a Boston company developing therapeutic immune modulators, closed a $37.5 million Series B financing led by two China investors, Sequoia Capital and Lyfe Capital. 

The financing round was also supported by existing Series A investors, VI Ventures and Nest.Bio Ventures, as well as new investors, Legend Star Capital and Proxima Ventures.

The company said the funding would transform HiFiBiO into a more mature biopharmaceutical company, with a stronger global presence and rich pipeline of novel antibodies for cancer and autoimmune disorders.

HiFiBiO Therapeutics made its first step towards becoming an innovative therapeutics company by appointing a new management team of experienced industry veterans.

HiFiBiO currently has more than 50 full-time employees operating out of three facilities in the USA, France and China.